Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS

Cardiovasc Res. 1999 Mar;41(3):754-64. doi: 10.1016/s0008-6363(98)00249-1.

Abstract

Objective: Venodilatation is a feature of endotoxaemia and sepsis. We have tested directly the hypothesis that three cytokines (IL-1 beta, TNF alpha and IL-6) generated during endotoxaemia affect venous tone in humans in vivo by increasing NO generation and explored whether the NO comes from the iNOS or eNOS isoform.

Design and intervention: Cytokines were given into a superficial vein in very low doses sufficient only to produce changes in the study vessel. The effects of cytokines on the response to noradrenaline were examined.

Results: IL-1 beta increased basal NO-induced dilatation in the study vein, and this was sufficient to attenuate the constrictor response to exogenous noradrenaline or sympathetic stimulation. The effects were maximal at 6 h and both NG-monomethyl-L-arginine and aminoguanidine caused significant reversal of the IL-1 beta effects. However, no induction of iNOS mRNA was detected in the tissue samples. Instead, mRNA encoding eNOS and GTP cyclohydrolase-1 was detected in all vessels.

Conclusion: The simplest explanation of these results is that IL-1 beta induces expression of GTP cyclohydrolase-1 which leads to increased generation of BH4 and activation of eNOS. This study identifies IL-1 beta as a key cytokine causing physiologically significant venodilatation in humans by increasing NO generation and suggests that this can occur even in the absence of iNOS expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginine / pharmacology
  • Biopterins / analogs & derivatives
  • Biopterins / pharmacology
  • Bradykinin / pharmacology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / enzymology
  • Enzyme Inhibitors / pharmacology
  • Female
  • Gene Expression
  • Guanidines / pharmacology
  • Humans
  • Interleukin-1 / pharmacology*
  • Interleukin-6 / pharmacology
  • Intracellular Signaling Peptides and Proteins
  • Male
  • Nitric Oxide Synthase / analysis
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Norepinephrine / pharmacology
  • Proteins / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Shock, Septic / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology
  • Vasoconstriction / drug effects*
  • Vasoconstrictor Agents / pharmacology
  • Vasodilator Agents / pharmacology
  • omega-N-Methylarginine / pharmacology

Substances

  • Enzyme Inhibitors
  • GCHFR protein, human
  • Guanidines
  • Interleukin-1
  • Interleukin-6
  • Intracellular Signaling Peptides and Proteins
  • Proteins
  • Tumor Necrosis Factor-alpha
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Biopterins
  • omega-N-Methylarginine
  • Arginine
  • NOS2 protein, human
  • NOS3 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • sapropterin
  • Bradykinin
  • pimagedine
  • Norepinephrine